

SUPPORTING MATERIAL

Isocyanide Chemistry Enabled by Continuous Flow Technology

Bruno Cerra,^a Cecile Blondeau,^a Rolando Cannalire,^b Mariateresa Giustiniano,^b Shiva Tali Shandiz^a
and Antimo Gioiello*^a

^aLaboratory of Medicinal and Advanced Synthetic Chemistry (Lab MASC), Department of Pharmaceutical Sciences, University of Perugia, Via del Liceo 1, Perugia, 06123, Italy.

^bDepartment of Pharmacy, University of Naples Federico II, via D. Montesano 49, 80131, Napoli, Italy.

*To whom correspondence should be addressed. Antimo Gioiello, Laboratory of Medicinal and Advanced Synthetic Chemistry (Lab MASC), Department of Pharmaceutical Sciences, University of Perugia, Via del Liceo 1, Perugia, 06123, Italy. Tel: +39 075 5852318; E-mail: antimo.gioiello@unipg.it

Table of Contents

- General methods	S3
- Flow synthesis of isocyanides	S3
- Table S1	S5
- Procedure for the yield determination of phenylisocyanide (1f)	S5
- Figure S1. Flow set-up adopted for the quantification of phenylisocyanide (1f)	S7
- Flow synthesis of 4-substituted 5-aminoimidazole derivatives	S7
- Flow synthesis of oxazoles	S8
- Continuous flow synthesis of lidocaine (12)	S9
- Copies of NMR spectra	S10

General methods

Unless otherwise noted, chemicals were obtained from commercial suppliers and used without further purification. Melting points were determined using an electrothermal apparatus (Buchi 535, B-535, Büchi, Switzerland) and are uncorrected. NMR spectra were recorded on a Bruker AC 400 MHz spectrometer in the indicated solvent. Chemical shifts are reported in parts per million (ppm) and are relative to CDCl_3 (7.26 ppm and 77.0 ppm), CD_3OD (3.33 ppm and 49.3 ppm) or d^6 -DMSO (2.49 ppm and 39.7 ppm). The abbreviations used are as follows: s, singlet; brs, broad singlet; d, doublet; dd, double doublet; ddd, doublet of doublet of doublet; t, triplet; q, quartet; quint, quintet; m, multiplet; brm, broad multiplet. Coupling constants (J) are reported in Hertz (Hz). Thin-layer chromatography was performed on aluminum backed silica plates (silica gel 60 F-254, Merck, Darmstadt, Germany). Spots were visualized by UV detector (λ : 254 nm) and/or by staining and warming with ninhydrin (5% wt in EtOH) or KMnO_4 . Flash chromatographic purifications were performed using Biotage Isolera™ Prime (Biotage, Uppsala, Sweden). All flow experiments were performed using a commercially available modular Syrris Asia system composed by two-channels Asia syringe pumps (Asia blue syringes, 0.50 mL/1.0 mL and Asia red syringes 2.5 mL/5 mL), external HPLC pumps (Jasco PU-980, Jasco, Easton, MD – USA), thermocouple-controlled coil reactors (1/16" OD, 0.8 mm ID, 10 mL, PTFE), glass tubular mesoreactors (Omnifit Labware DIBA HIT™ column, ID \times L 6.6 mm \times 150 mm), T-shaped mixing elements (0.5 mm ID), back pressure regulators (BPR, 40 psi and 100 psi, PEEK, 1/16" OD, 1/4"-28), 4-way valves (PTFE, 1/4"-28, 0.5-4 mm OD, 1.5 mm ID, DIBA) and a fraction collector (Gilson FC 203B, Gilson Inc., Middleton, WI – USA). High resolution mass spectrometry (HRMS) measurements were recorded on Agilent 6500 Q-TOF series instrument (Agilent technologies, USA). The MS system was set with an electrospray ionization source (ESI) in the negative mode with optimized parameters. MassHunter software version B.05.01 (Agilent Technology) was used to control the LC–MS/MS system, for data prediction, acquisition, analysis, and processing. Samples were dissolved in MeOH.

Flow synthesis of isocyanides

A solution of formamide **2a-j** (1.8 mmol, 0.6 M) and Et_3N (9 mmol, 3 M) in CHCl_3 (3 mL) and a solution of POCl_3 (1.8 mmol, 0.6 M) in CHCl_3 (3 mL) were injected through the loops and pumped with a total flow rate of 0.5 mL min^{-1} . After loading and switching the 6-way valves injector, the components were mixed in a T-junction and flowed through a 10 mL coil reactor at 25 °C. The reactor outcome was filtered through an Omnifit Labware DIBA HIT™ column (ID \times L: 6.6 mm \times 150

mm) packed with silica gel (70-230 mesh, 1.5 g/ mmol⁻¹). A back pressure regulator (BPR, 100 psi) was used to pressurize the system. The reaction mixture was collected by an automated fraction collector into sealed vials (4 mL for each fraction, 5 min collecting time). The reaction yield was determined by calibrated quantitative ¹H-NMR analysis (400 MHz, CDCl₃) using dimethyl sulfone (TraceCERT[®]) as the internal standard. Based on the determined yield and title, the solution of the desired isocyanide **1** in CHCl₃ can be varied (diluted) to reach the concentration required for the next post-modification step. For substrate **2a**, the reaction was scaled up 18 mmol (2 g) using the same conditions described above. The reactor outcome was filtered through a Michel-Miller columns (ID × L: 15 mm x 250 mm) packed with silica (70-230 mesh, 1.5 g/ mmol⁻¹, 27 g) and the desired *t*-butylisocyanide (**1a**) in 84% yield.

***t*-Butylisocyanide (1a).** Yield: 89%. ¹H-NMR (400 MHz, CDCl₃): δ 1.41 (s, 9H, 3 x CH₃). ¹³C-NMR (100.6 MHz, CDCl₃): δ 30.7, 54.1, 152.2.

Benzylisocyanide (1b). Yield: 87%. ¹H-NMR (400 MHz, CDCl₃): δ 4.56 (s, 2H, CH₂), 7.24-7.31 (m, 5H, C₆H₅). ¹³C-NMR (100.6 MHz, CDCl₃): δ 45.7, 126.8, 128.6, 129.1, 132.5, 157.7.

Cyclohexylisocyanide (1c). Yield: 79%. ¹H-NMR (400 MHz, CDCl₃): δ 1.35-1.47 (m, 4H, 2 x CH₂), 1.66-1.78 (m, 4H, 2 x CH₂), 1.86-1.88 (m, 2H, CH₂), 3.59 (brs, 1H, CH). ¹³C-NMR (100.6 MHz, CDCl₃): δ 22.9, 25.1, 32.8, 51.8, 153.9.

Cyclopropylisocyanide (1d). Yield: 69%. ¹H-NMR (400 MHz, CDCl₃): δ 0.83-0.85 (m, 2H, CH₂), 0.93-0.95 (s, 2H, CH₂), 2.65-2.71 (m, 1H, CH), ¹³C-NMR (100.6 MHz, CDCl₃): δ 7.5 (2x), 75.8, 153.5.

2,6-Dimethylphenylisocyanide (1g). Pale yellow solid. Reaction performed at 0.15 M concentration of **2g**. Isolated yield: 44%. ¹H-NMR (400 MHz, CDCl₃): δ 2.42 (s, 6H, 2 x CH₃), 7.09 (d, *J* = 4.10 Hz, 2H, 3,5-CH), 7.18 (t, *J* = 8.12 Hz, 1H, 4-CH). ¹³C-NMR (100.6 MHz, CDCl₃): δ 19.1, 127.9 (2x), 128.8, 135.0, 167.6.

4-Methoxyphenylisocyanide (1h). Yield: 77%. ¹H-NMR (400 MHz, CDCl₃): δ 3.82 (s, 3H, CH₃), 6.87 (d, *J* = 9.02 Hz, 2H, 3,5-CH), 6.31 (d, *J* = 9.10 Hz, 2H, 2,6-CH). ¹³C-NMR (100.6 MHz, CDCl₃): δ 55.5, 114.5, 127.7, 159.8, 161.5.

4-Chlorophenylisocyanide (1i). Reaction performed at 0.36 M concentration of **2i**. Yield: 79%. ¹H-NMR (400 MHz, CDCl₃): 7.28 (d, *J* = 8.67 Hz, 2H), 7.33 (d, *J* = 8.51 Hz, 2H). ¹³C-NMR (100.6 MHz, CDCl₃): δ 124.8, 127.7, 129.6, 135.1, 165.2.

Ethylisocynoacetate (1j). Colorless oil. Isolated yield: 80%. ¹H-NMR (400 MHz, CDCl₃): δ 1.27 (t, 3H, CH₂CH₃), 4.20-4.26 (m, 4H, CH₂CH₃ + CH₂NC). ¹³C-NMR (100.6 MHz, CDCl₃): δ 13.9, 43.5, 62.7, 160.8, 163.9.

Table S1. Flow synthesis of 2,6-dimethylphenyl isocyanide (**1g**) under diverse reaction conditions.

Entry	Base (equiv.)	Solvent	[SM]	Solubility	Yield ^a
1	Et ₂ NH	Et ₂ NH	0.1-0.6	Not soluble	-
2	Et ₂ NH (10)	10% DMSO in CHCl ₃	0.6	Soluble	Traces
3	Et ₃ N (5)	10% 1,2-diCl-Ph in CHCl ₃	0.1-0.6	Not soluble	-
4	Et ₃ N (5)	50% 1,2-diCl-Ph in CHCl ₃	0.15-0.6	Soluble at 0.3 M	Traces
5	Et ₃ N (5)	20% (v/v) DMSO in CHCl ₃	0.5-0.6	Soluble at 0.45 M	Traces
6	Et ₃ N (5)	10% (v/v) DMSO in CHCl ₃	0.35-0.4	Soluble at 0.35 M	22%
7	Et ₃ N (5)	5% (v/v) DMSO in CHCl ₃	0.15-0.6	Soluble at 0.15 M	44%

^aIsolated yield.

Procedure for the yield determination of phenylisocyanide (**1f**)

A solution of phenyl formamide (**2f**, 1.8 mmol, 0.6 M) and Et₃N (9 mmol, 3 M) in CHCl₃ (3 mL) and a solution of POCl₃ (1.8 mmol, 0.6 M) in CHCl₃ (3 mL) were injected through the loops and pumped with a total flow rate of 0.5 mL min⁻¹. After loading and switching the 6-way valves injector, the components were mixed in a T-junction and flowed through a 10 mL coil reactor (t= 20 min) at 25 °C. The reactor outcome was filtered through an Omnifit Labware DIBA HIT™ column (ID × L: 6.6 mm x 150 mm) packed with silica gel (1.5 g/mmol⁻¹) under a 100 psi BPR regime. The isocyanide thus formed (0.45 M) was readily reacted with a solution of 4-bromoaniline (1 equiv., 1 M in MeOH) and a solution of 2-pyrindincarboxaldehyde (1 equiv., 1 M in MeOH) with a total flow rate of 0.1 mL min⁻¹. The resulting mixture was flowed through a four-ways mixer with a solution of fumaric acid monoethyl ester (1 equiv., 1 M in MeOH) and phenylisocyanide (1 equiv., 0.18 mmol, 0.3 M in CHCl₃). The mixture was pumped through a 10 mL reactor coil (10 mL, t= 66 min) heated

at 55 °C. The system was maintained at constant pressure through a BPR element (40 psi). The reactor outcome was collected, concentrated under reduced pressure and purified by automated silica gel flash chromatography (Eluent: Petroleum ether/EtOAc from 100:0 to 0:100, v/v). Yield (over two steps): 36%. When the same reaction was performed using the commercially available phenylisocyanide (**1f**, CAS: 931-54-4, 97% purity, Merck) under the same flow conditions, the corresponding β -lactam derivative was isolated in 42% yield. Therefore, the yield of phenylisocyanide (**1f**) was 87%.

Continuous flow synthesis of oxazoles

A solution of formamide **2a** (1.8 mmol, 0.6 M) and Et₃N (9 mmol, 3 M) in CHCl₃ (3 mL) and a solution of POCl₃ (1.8 mmol, 0.6 M) in CHCl₃ (3 mL) were pumped with a total flow rate of 0.5 mL min⁻¹ through a 10 mL coil reactor at 25 °C. The reactor outcome was filtered through an Omnifit Labware DIBA HIT™ column (ID × L: 6.6 mm x 150 mm) packed with silica gel (70-230 mesh, 1.5 g/mmol⁻¹) under 100 psi BPR regime. The CHCl₃ solution of *t*-butylisocyanide (**1a**) (2 equiv., 0.3 M) collected into a Erlenmeyer flask with screw cap was then mixed in a four-ways mixer with a solution of benzoic acid (**3**) (1 equiv., 1 M in CHCl₃) and of phenylglyoxal (**4**) (1 equiv., 1 M in CHCl₃) with a residence time of 33 minutes within a 10 mL coil reactor at 25 °C. The system was maintained at constant pressure through a BPR element (40 psi). The reactor outcome was collected, dried under *vacuo* and crystallized from Et₂O. The product was dissolved in AcOH (0.5 M) and treated with ammonium formate in AcOH at reflux for 1 h. The mixture was allowed to cool to 25 °C and the solid was collected by filtration.

N-(tert-Butyl)-2,4-diphenyloxazole-5-carboxamide (7). White solid (m.p.: 214-216 °C). Yield: 75%. ¹H-NMR (400 MHz, *d*⁶-DMSO): δ 1.37 (s, 9H, 3 x CH₃), 7.40-8.08 (m, 10H, Ar). ¹³C-NMR (100.6 MHz, *d*⁶-DMSO): δ 29.1, 50.3, 126.1, 128.2, 128.5, 129.2, 129.3, 129.9 (2x), 130.1, 132.2, 134.4, 144.8, 162.4. HRMS–ESI: m/z [M + H]⁺ calcd for C₁₃H₁₇ClN₃⁺: 320.1525; found: 320.1529.

N-(Cyclohexyl)-2,4-diphenyloxazole-5-carboxamide (8).¹ White solid (m.p.: 168-170 °C). Yield: 52%. ¹H-NMR (400 MHz, CDCl₃): δ 1.18-2.08 (m, 10H, 5 x CH₂ cyclohexane), 3.96-4.01 (m, 1H, CH cyclohexane), 6.28 (d, *J* = 8.1 Hz, 1H, NH), 7.40-8.29 (m, 10H, Ar). ¹³C-NMR (100.6 MHz, CDCl₃): δ 24.9, 25.4, 33.1, 48.4, 126.4, 127.0, 128.1, 128.8, 129.3 (2x), 130.4, 131.3, 138.8, 144.3, 157.0, 160.0.

Continuous flow synthesis of 4-substituted 5-aminoimidazole

A solution of formamide **2a** (1.8 mmol, 0.6 M) and Et₃N (9 mmol, 3 M) in CHCl₃ (3 mL) and a solution of POCl₃ (1.8 mmol, 0.6 M) in CHCl₃ (3 mL) were pumped with a total flow rate of 0.5 mL min⁻¹ through a 10 mL coil reactor at 25 °C. The reactor outcome was filtered through an Omnifit Labware DIBA HIT™ column (ID × L: 6.6 mm x 150 mm) packed with silica gel (70-230 mesh, 1.5 g/ mmol⁻¹) under 100 psi BPR regime. The CHCl₃ solution of *t*-butylisocyanide (**1a**) (2 equiv., 0.2 M) collected into a Erlenmeyer flask with screw cap was then pumped and mixed with CHCl₃ solutions of the desired *p*-substituted phenyl 2-amino-acetonitrile (1 equiv., 0.1 M) and Yb(OTf)₃ (0.6 equiv., 0.06 M) with a total flow rate of 1.0 mL min⁻¹. The reaction mixture was flowed through a 10 mL coil reactor heated at 130 °C using a 140 psi BPR. The out flow was washed with an aqueous saturated solution of NaHCO₃, H₂O, brine, dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The crude was purified by automated silica gel flash chromatography (Eluent: CH₂Cl₂/MeOH from 100:0 to 95:5, v/v). The product was dissolved in dry 1,4-dioxane (2 mL) and treated with 4 M solution of HCl in 1,4-dioxane (1 mL) at 0 °C. The solvent was removed under *vacuo* and the product was precipitated and triturated from *n*-hexane/Et₂O to give the chlorohydrate form.

1-*tert*-Butyl-4-(4'-chlorophenyl)-5-aminoimidazole chlorohydrate (10a).² Orange amorphous solid. Yield: 51%. ¹H-NMR (400 MHz, CD₃OD): δ 1.80 (s, 9H, 3 x CH₃), 7.52-7.54 (m, 2H, 3'-CH + 5'-CH), 7.61-7.63 (m, 2H, 2'-CH + 6'-CH), 8.67 (s, 1H, 2-CH). ¹³C-NMR (100.6 MHz, CD₃OD): δ 27.4, 60.2, 116.8, 126.1, 128.1, 129.0, 134.1, 134.9. HRMS-ESI: *m/z* [M + H]⁺ calcd for C₁₃H₁₇ClN₃⁺: 250.1106; found: 250.1106.

1-*tert*-Butyl-4-phenyl-5-aminoimidazole chlorohydrate (10b).² Grey solid (m.p.: 59-61 °C). Yield: 40%. ¹H-NMR (400 MHz, CDCl₃): δ 1.69 (s, 9H, 3 x CH₃), 3.31 (brs, 2H), 7.21 (t, *J* = 8.06 Hz, 1H, 4'-CH), 7.38-7.41 (m, 3H, 3'-CH + 5'-CH + 2-CH), 7.68 (d, *J* = 8.05 Hz, 2H, 2'-CH + 6'-CH). ¹³C-NMR (100.6 MHz, CDCl₃): δ 29.6, 55.9, 125.8, 126.1, 128.4, 128.6, 129.8, 131.4, 135.2. HRMS-ESI: *m/z* [M + H]⁺ calcd for C₁₃H₁₈N₃⁺: 216.1495; found: 216.1496.

1-*tert*-Butyl-4-(((4'-morpholyn)-4-yl)phenyl)-5-aminoimidazole chlorohydrate (10c).² Brown solid (m.p.: 59-62 °C). Yield: 34%. ¹H-NMR (400 MHz, CDCl₃): δ 1.60 (s, 9H, 3 x CH₃), 3.16-3.28 [m, 8H, -O(CH₂CH₂)₂N-], 7.35 (d, *J* = 8.08 Hz, 2H, 3'-CH + 5'-CH), 7.71 (d, *J* = 8.06 Hz, 2H, 2'-CH + 6'-CH), 8.46 (s, 1H, 2-CH). ¹³C-NMR (100.6 MHz, CDCl₃): δ 27.2, 48.9, 61.2, 66.6, 114.3, 115.7, 117.7, 128.3,


130.3, 151.6, 153.5. HRMS–ESI: m/z $[M + H]^+$ calcd for $C_{13}H_{18}N_3^+$: 336.1717; found: 336.1719.

Continuous flow synthesis of lidocaine (**12**)³



A solution of formamide **2g** (0.15 M) and Et_3N (0.75 M) in $CHCl_3/DMSO$ (95:5, v/v) and a $CHCl_3$ solution of $POCl_3$ (0.15 M) were pumped with a total flow rate of 0.5 mL min^{-1} through a 10 mL coil reactor at 25 °C. The reactor outcome was collected into a sealed flask, concentrated under reduced pressure ($T: \leq 30\text{ °C}$) and purified by automated flash chromatography on silica gel (Biotage Isolara One, Eluent: *n*-hexane/ Et_2O from 100:0 to 60:40, v/v). The resulting 2,6-dimethylphenyl isocyanide (**1g**, 44% isolated yield) was dissolved in $CHCl_3$ (0.1 M) and mixed *via* a four ways connector with a MeOH solution of diethylamine (0.1 M) and a solution containing formaldehyde (0.1 M in MeOH) and 2-hydroxymethylbenzoic (**11**) (0.1 M in MeOH), and reacted in a 10 mL coil reactor ($\tau = 66\text{ min}$) heated at 80° C. The crude reaction mixture was loaded into a automated flash chromatography to afford 2-(diethylamino)-*N*-(2,6-dimethylphenyl)acetamide (lidocaine, **12**) in 69% yield.

White solid (m.p.: 76-78 °C). 1H -NMR (400 MHz, $CDCl_3$): δ 1.14 (t, $J = 7.6$, 6H, 2 x CH_2CH_3), 2.23 (s, 6H, 2 x Ph- CH_3), 2.69 (q, $J = 7.6\text{ Hz}$, 4H, 2 x CH_2CH_3), 3.22 (s, 2H, CH_2NEt_2), 7.09-7.12 (m, 3H, -CH). ^{13}C -NMR (100.6 MHz, $CDCl_3$): δ 12.6, 18.5, 48.9, 57.4, 127.0, 128.1, 133.9, 135.0, 170.2.

Copies of NMR Spectra




¹³C-NMR (CDCl₃, 100.6 MHz)
t-Butylisocyanide (200 μL CHCl₃ solution 0.45 M theoretical + 400 μL DMS 0.0887 M in CDCl₃)




¹H-NMR (CDCl₃, 400 MHz)
Benzylisocyanide (200 μL CHCl₃ solution 0.45 M theoretical + 400 μL DMS 0.225 M in CDCl₃)


2975.21
2974.31
2966.38
2965.74
2964.09
2959.59
2951.18
2947.44
2944.97
2942.24
2941.36
2940.55
2939.90
2939.20
2938.44
2905.32




1859.28
1187.40
648.05
36.84
36.21




¹³C-NMR (CDCl₃, 100.6 MHz)
Benzylisocyanide (200 μL CHCl₃ solution 0.45 M theoretical + 400 μL DMS 0.225 M in CDCl₃)




¹H-NMR (CDCl₃, 400 MHz)
Cyclohexylisocyanide (200 μL CHCl₃ solution 0.45 M theoretical + 400 μL DMS 0.0928 M)




¹³C-NMR (CDCl₃, 100.6 MHz)
Cyclohexylisocyanide (200 μL CHCl₃ solution 0.45 M theoretical + 400 μL DMS 0.0928 M)





¹H-NMR (CDCl₃, 400 MHz)
Cyclopropylisocyanide (200 μL CHCl₃ solution 0.45 M theoretical + 400 μL DMS 0.1232 M)




¹³C-NMR (CDCl₃, 100.6 MHz)
Cyclopropylisocyanide (200 μL CHCl₃ solution 0.45 M theoretical + 400 μL DMS 0.1232 M)




¹H-NMR (CDCl₃, 400 MHz)
2,6-Dimethylphenylisocyanide (After silica gel filtration)




¹³C-NMR (CDCl₃, 100.6 MHz)
2,6-Dimethylphenylisocyanide (After silica gel filtration)



¹H-NMR (CDCl₃, 400 MHz)
p-methoxyphenylisocyanide (200 μL CHCl₃ solution 0.45 M theoretical + 400 μL DMS 0.225 M)




¹³C-NMR (CDCl₃, 100.6 MHz)
p-methoxyphenylisocyanide (200 μL CHCl₃ solution 0.45 M theoretical + 400 μL DMS 0.225 M)




¹H-NMR (CDCl₃, 400 MHz)
4-Chlorophenylisocyanide (200 μL CHCl₃ solution 0.45 M theoretical + 400 μL DMS 0.410 M in CDCl₃)



2935.78
2927.27
2917.77
2909.10




H₂





¹³C-NMR (CDCl₃, 400 MHz)
4-Chlorophenylisocyanide (200 μL CHCl₃ solution 0.45 M theoretical + 400 μL DMS 0.410 M in CDCl₃)




¹H-NMR (CDCl₃, 400 MHz)
Ethylisocyanacetate (After silica gel filtration)





¹³C-NMR (CDCl₃, 100.6 MHz)
Ethylisocyanacetate (After silica gel filtration)




¹H-NMR (CD₃OD, 400 MHz)
1-Tert-butyl-4-(4'-chlorophenyl)-5-aminoimidazole chlorohydrate




¹³C-NMR (CD₃OD, 100.6 MHz)
1-Tert-butyl-4-(4'-chlorophenyl)-5-aminoimidazole chlorohydrate




**¹H-NMR (CDCl₃, 400 MHz)
1-Tert-butyl-4-phenyl-5-aminoimidazole chlorohydrate**




¹³C-NMR (CDCl₃, 100.6 MHz)
1-Tert-butyl-4-phenyl-5-aminoimidazole chlorohydrate







¹³C-NMR (CDCl₃, 100.6 MHz)
1-Tert-butyl-4-[[[(4'-morpholin)-4-yl]phenyl]-5-aminoimidazole chlorohydrate (93)






¹H-NMR (d⁶-DMSO, 400 MHz)
N-(tert-butyl)-2,4-diphenyloxazole-5-carboxamide





¹³C-NMR (d⁶-DMSO, 100.6 MHz)
N-(tert-butyl)-2,4-diphenyloxazole-5-carboxamide




¹H-NMR (CDCl₃, 400 MHz)
N-(Cyclohexyl)-2,4-diphenyloxazole-5-carboxamide




Hz






¹H-NMR (CDCl₃, 400 MHz)
2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide (lidocaine, 25)



¹³C-NMR (CDCl₃, 100.6 MHz)
2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide (lidocaine, 25)



Referenzen and notes

1. R. Bossio, S. Marcaccini and R. Pepino. *Liebigs Ann. Chem.* 1991, **10**, 1107-1108.
2. R. Cannalire, C. Russo, B. Cerra, A. Gioiello, F. Brunelli, G. C. Tron and M. Giustiniano, *Mol. Diversity*, 2022.
3. a) I. Ugi and C. Steinbrückner, *Patent*, 1966, US3247200; b) D. E. Fitzpatrick, T. Maujean, A. C. Evans and S. V. Ley, *Angew. Chem. Int. Ed.* 2018, **57**, 15128-15132. c) M. Lee, N. J. Vosburg, E. A. Shimizu, M. A. Rentería-Gómez, R. Gámez-Montaña and D. A. Vosburg, *J. Chem. Educ.*, 2022, **99**, 2399–2402.